This uncertainty was highlighted in a systematic review and cost-effectiveness analysis conducted to assess the role of biomarkers, including Nephrocheck, ARCHITECT urine NGAL, and BioPorto NGAL, in early AKI detection. The gene discussed is LCN2; the disease is acute kidney injury.